Nasdaq
$2.29▼ 0.65%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $106.7MShares out 46.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 8.20After-hours26.08.21 05:403Ownership#●●●
Minerva Neurosciences, Inc.
Joseph H. Reilly, an officer of Minerva Neurosciences, Inc., has executed a power of attorney for the filing of SEC Forms 3, 4, and 5. This grants designated attorneys-in-fact the authority to prepare and submit required disclosures regarding his securities holdings and transactions on his behalf.…more
$2.29-0.65%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.20After-hours26.08.21 05:383Ownership
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. filed a Power of Attorney on August 7, 2026, authorizing designated company representatives to prepare and file Forms 3, 4, and 5 with the SEC on behalf of Anthony Aliquo. This administrative action facilitates compliance with Section 16(a) of the Securities Exchange Act regarding the reporting of beneficial ownership and transactions by officers and directors.…more
$2.29-0.65%vs prev closeView filingShare - 8.12After-hours26.08.13 05:058-KKey event
Minerva Neurosciences, Inc.
Minerva Neurosciences appointed Anthony Aliquo as Chief Accounting Officer, effective August 10, 2026. Fred Ahlholm will step down as principal accounting officer while continuing his role as Chief Financial Officer, and Aliquo's annual base salary has been increased to $296,696.…more
$2.29-0.65%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.28Pre-market26.08.28 21:00#●●●#●●●
Minerva Neurosciences to Attend Upcoming Investor Conferences
Minerva Neurosciences announced that its management will participate in the Wells Fargo and Cantor Global Healthcare conferences in September. These events will focus on investor meetings and discussions rather than new material business developments.…more
$2.29-0.65%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.7Pre-market26.08.07 20:00
●●●●●●●● ●●●●● ●●●●●●
미네르바 뉴로사이언스는 조현병 치료제 후보물질 '롤루페리돈'의 임상 3상을 순조롭게 진행 중이며 2027년 하반기 결과 발표를 목표로 하고 있습니다. 회사는 임상 비용 증가로 인해 영업 손실이 확대되었으나, 핵심 파이프라인 개발에 집중하며 연구 역량을 강화하고 있습니다.…more
$2.29-0.65%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report